Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep 18;9(9):e04646.
doi: 10.1002/ccr3.4646. eCollection 2021 Sep.

Effectiveness of aprepitant in post-acute COVID19 syndrome

Rocío Reinoso-Arija  1 , Cecilia López-Ramírez  1 , José Antonio Jimenez-Ruiz  2 , José Luis López-Campos  1   3
Affiliations
Case Reports

Effectiveness of aprepitant in post-acute COVID19 syndrome

Rocío Reinoso-Arija et al. Clin Case Rep. .

Abstract

This is the first case of a patient taking aprepitant for a post-acute COVID-19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.

Keywords: COVID19; SARS‐CoV‐2; aprepitant; post‐acute.

PubMed Disclaimer

Conflict of interest statement

JLLC has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bayer, Boehringer Ingelheim, Cantabria Pharma, Chiesi, CSL Behring, Esteve, Faes, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, MSD, Novartis, Pfizer, Rovi, Teva and Takeda. The other authors declare no conflicts of interest.

References

    1. Nalbandian A, Sehgal K, Gupta A, et al. Post‐acute COVID‐19 syndrome. Nat Med. 2021;27(4):601‐615. 10.1038/s41591-021-01283-z - DOI - PMC - PubMed
    1. Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low‐risk individuals with post‐COVID‐19 syndrome: a prospective, community‐based study. BMJ Open. 2021;11(3):e048391. 10.1136/bmjopen-2020-048391 - DOI - PMC - PubMed
    1. Cares‐Marambio K, Montenegro‐Jiménez Y, Torres‐Castro R, et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis. Chronic Respir Dis. 2021;18:14799731211002240. 10.1177/14799731211002240 - DOI - PMC - PubMed
    1. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID‐19 survivors in Wuhan, China: a single‐centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89‐95. 10.1016/j.cmi.2020.09.023 - DOI - PMC - PubMed
    1. Mehboob R, Ahmad FJ, Qayyum A, et al. Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid‐19 patients and potentiates respiratory recovery: A novel therapeutic approach. medRxiv 2020:2020.08.01.20166678. 10.1101/2020.08.01.20166678 - DOI

Publication types